Engineered escherichia coli and application thereof
By developing E. coli that knocks out type I pilus and expresses fusion protein E. coli, the toxicity, cost and durability of existing CAF-targeting strategies is solved, and specific targeting and tumor suppression in vivo is achieved. Efficient and safe anti-cancer effects.
Patent Information
- Application Number
- CN202411060906.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-02
AI Technical Summary
Existing cancer-associated fibroblasts (CAF) strategies have potential systemic toxicity, high cost, poor durability, low efficiency, and high storage and transportation costs, and personalized CAR-T cell preparation and viral vector vaccines The application effect is not good.
Develop an engineered E. coli by knocking out the type I pilus gene, expressing a fusion protein containing membrane anchoring domains and targeting domains, for targeting binding and killing tumor cells, reducing nonspecific adhesion, and in Tumor colonization increases cytotoxic molecular secretion to inhibit tumor growth.
It realizes specific targeting of tumor cells in vivo, reduces non-specific adhesion, improves anti-tumor immune response, has high biosafety and significant anti-cancer effects, and can detect bacterial enrichment in a short time, making it convenient for antibody screening. And colonization within the tumor inhibits tumor growth.
Smart Images

Figure HDA0004978276260000011 
Figure HDA0004978276260000012 
Figure HDA0004978276260000013
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to an engineered Escherichia coli and an application thereof. Background Art
[0002] Cancer-associated fibroblasts (CAFs), as one of the most abundant matrix components in the tumor microenvironment, can enhance the ability of tumor immune escape, distal migration and local drug resistance, and have been widely studied as target cells for tumor therapy. Targeting the fibroblast activated protein (FAP) biomarker that is highly specifically expressed on the surface of CAFs, the current strategies for targeting cancer-associated fibroblasts include FAP antibodies, FAP inhibitors, FAP-targeted liposome particles (FAP-LNPs), FAP vaccines, and FAP-targeted chimeric antigen receptor (CAR) T cells. The ideal strategy for targeting CAFs should have high safety, the ability to continuously and effectively eliminate the tumor-promoting function of CAFs and activate the anti-tumor immune response in vivo, and appropriate cost. Among the existing strategies, the in vivo application of liposomes has the problem of potential systemic toxicity; the personalized preparation and application of CAR-T has the problems of high consumption of time and money, low durability and poor clinical effect; although DNA vaccines and viral vector vaccines for FAP have the potential for sustained immunity, they are less efficient and require larger doses, and the storage conditions of viral vector vaccines are relatively strict, and the storage and transportation costs are high. Summary of the invention
[0003] In order to solve at least one of the above problems, the present disclosure provides an engineered Escherichia coli and applications thereof, wherein the engineered Escherichia coli has reduced nonspecific adhesion to cells and is capable of targeted binding and / or killing tumor cells.
[0004] According to one aspect of the present disclosure, an engineered Escherichia coli is provided, in which one or more coding genes in the fimA~fimH operon of type I fimbriae are knocked out, and the cell membrane of the engineered Escherichia coli carries a fusion protein, and the fusion protein includes: a membrane anchoring domain, which includes the full length or a fragment of an autotransporter protein derived from bacteria; and a targeting domain.
[0005] In some embodiments, the E. coli lacks or partially lacks a pilus gene. In some embodiments, the pilus gene includes, but is not limited to, fimA, fimB, fimC, fimD, fimE, fimF, fimG, fimH or fimI. In some embodiments, the E. coli is knocked out of one or more coding genes in the fimA-H operon encoding type I pilus.
[0006] In some embodiments, the genome of the engineered E. coli has a nucleotide sequence as shown in SEQ ID NO: 25 or 26, or a nucleotide sequence having at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity thereto.
[0007] In some embodiments, the engineered Escherichia coli can be selected from, but not limited to, BL21, MG1655, DH5α, Transetta, Rosetta Blue, Origami, Rosetta or Trans5α.
[0008] In some embodiments, the membrane anchoring domain comprises a Ve-type autotransporter or a fragment thereof derived from bacteria.
[0009] In some embodiments, the fusion protein comprises the membrane anchoring domain and the targeting domain from the N-terminus to the C-terminus.
[0010] In some embodiments, the membrane anchoring domain comprises the full length or a fragment thereof of intimin or intimin-like adhesin (YeeJ).
[0011] In some embodiments, the membrane anchoring domain comprises an amino acid sequence as shown in SEQ ID NO: 1 or 2, or an amino acid sequence having at least 85% sequence identity thereto.
[0012] In some embodiments, the membrane anchoring domain comprises an amino acid sequence as shown in SEQ ID NO: 1 or 2, or an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity thereto.
[0013] In some embodiments, the targeting domain comprises an antibody or an antigen-binding fragment thereof that specifically binds to a tumor cell surface antigen. In some embodiments, the antigen-binding fragment comprises, but is not limited to, a scFab, scFv, di-scFv or a single domain antibody (VHH) that specifically binds to a tumor cell surface antigen.
[0014] In some embodiments, the targeting domain comprises a single domain antibody against fibroblast activation protein (FAP). In some embodiments, the targeting domain comprises an amino acid sequence as shown in SEQ ID NO: 3 or 4, or an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity thereto.
[0015] The engineered Escherichia coli disclosed in the present invention has reduced non-specific adhesion to cells, especially tumor cells, and is capable of targeted binding and / or killing tumor cells.
[0016] In some embodiments, the tumor cells include, but are not limited to, solid tumors, soft tissue tumors, hematopoietic tumors, adenoma, primary tumors and metastatic tumors. In a specific embodiment, the tumor cells include tumor cells or stromal cells thereof. In a specific embodiment, the tumor cells include cancer-associated fibroblasts. In some embodiments, the tumor cell surface may express fibroblast activation protein (FAP).
[0017] In some embodiments, the targeting domain is protein-tagged.
[0018] In some embodiments, the protein tag is arbitrarily selected from the conventional tags used in the art. For example, the protein tag is selected from but not limited to His tag, Flag tag, HA tag, c-Myc tag, V5 tag, AviTag tag, GST (glutathione sulfhydryl transferase) tag, SUMO tag, Halo tag, SNAP tag, MBP (maltose binding protein) tag, fluorescent protein (e.g., eGFP / eCFP / eYFP / mCherry), one or more of luciferase.
[0019] In some embodiments, any two of the membrane anchoring domain, the targeting domain and the anti-cancer substance structure are directly or indirectly connected.
[0020] In some embodiments, any two of the membrane anchoring domain, the targeting domain and the anticancer substance domain are indirectly connected via a linker.
[0021] In some embodiments, the linker includes a flexible linker and a rigid linker.
[0022] In some embodiments, the linker comprises (G n S) m 、(G) n or (EA3K) n One or more of the amino acid sequences shown, wherein n and m are each independently selected from integers of 0 to 5.
[0023] In some embodiments, the fusion protein comprises an amino acid sequence as shown in SEQ ID NO:3 or 4, or an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity thereto.
[0024] In some embodiments, the targeting domain is displayed on the cell membrane surface of the engineered E. coli.
[0025] In some embodiments, one end of the membrane anchoring domain is inserted into the cell membrane of the engineered E. coli.
[0026] In some embodiments, the engineered E. coli also expresses a cytotoxic molecule or an active fragment thereof.
[0027] In some embodiments, the cytotoxic molecule includes, but is not limited to, IFNγ, GM-CSF, TNFα, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-16, IL-17, IL-23, IL-32, granzyme B, perforin, or a combination thereof.
[0028] In some embodiments, the cytotoxic molecule may include cytolysin A. In some embodiments, the cytotoxic molecule may have an amino acid sequence as shown in SEQ ID NO: 8, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity thereto.
[0029] According to yet another aspect of the present disclosure, a method for preparing the engineered Escherichia coli of the present disclosure is provided.
[0030] In some embodiments, the method includes: 1) using the CRISPR / Cas gene editing system to knock out the pilus gene of Escherichia coli to obtain Escherichia coli with the pilus gene knocked out; 2) expressing a fusion protein in the Escherichia coli with the pilus gene knocked out, wherein the fusion protein includes a membrane anchoring domain and a targeting domain.
[0031] In some embodiments, the fimbrial gene includes, but is not limited to, fimA, fimB, fimC, fimD, fimE, fimF, fimG, fimH or fimI. In some embodiments, the Escherichia coli is knocked out of one or more coding genes in the fimA-H operon of type I fimbrial, preferably knocked out of the coding genes of the fimA-H operon of type I fimbrial.
[0032] In some embodiments, the method uses an sgRNA targeting fimB and / or fimH. In some embodiments, the sgRNA targeting fimB may have a nucleotide sequence as shown in SEQ ID NO: 15 or 16. In some embodiments, the sgRNA targeting fimH may have a nucleotide sequence as shown in SEQ ID NO: 17 or 18.
[0033] In some embodiments, the method further comprises expressing a cytotoxic molecule in the engineered E. coli.
[0034] According to another aspect of the present disclosure, a composition is provided, which includes the engineered Escherichia coli described in the present disclosure, or a culture supernatant derived from the engineered Escherichia coli.
[0035] According to another aspect of the present disclosure, a method for detecting a tumor is provided, the method comprising using the engineered Escherichia coli of the present disclosure, and observing the aggregation degree of the engineered Escherichia coli around tumor cells.
[0036] In some embodiments, the tumor cells include, but are not limited to, tumor cells and / or tumor stromal cells in solid tumors, soft tissue tumors, hematopoietic tumors, adenoma, primary tumors, and metastatic tumors.
[0037] According to yet another aspect of the present disclosure, a method for screening antibodies or antigen-binding fragments thereof is provided, the method comprising using the engineered Escherichia coli of the present disclosure to screen target antibodies or antigen-binding fragments thereof.
[0038] According to another aspect of the present disclosure, provided is the use of the above-mentioned engineered Escherichia coli of the present disclosure in detecting, treating or preventing tumor cells.
[0039] According to another aspect of the present disclosure, the use of the above-mentioned engineered Escherichia coli of the present disclosure in preparing a reagent for detecting, treating or preventing a tumor is provided. In some embodiments, the tumor includes, but is not limited to, a solid tumor, a soft tissue tumor, a hematopoietic tumor, a glandular tumor, a primary tumor and a metastatic tumor, such as breast cancer and / or colorectal cancer.
[0040] Beneficial effects:
[0041] The present disclosure discovered that the engineered bacteria had their natural type I pili knocked out, which could effectively reduce the nonspecific targeted adhesion rate of the engineered bacteria without changing the growth and morphology of the engineered bacteria, which provides new ideas for the development of other engineered bacteria for specific targeting.
[0042] The specific adhesion rate of cells expressing adhesins fused with single-domain antibodies to cells is significantly increased. By replacing the single-domain antibody sequence displayed extracellularly by artificially synthesized adhesins (intimin or YeeJ) of engineered bacteria, flexible targeting of various target cells can be achieved, which has the potential to become a precision treatment toolkit.
[0043] Under in vitro co-culture conditions, the enrichment of engineered bacteria can be detected in even less than 1 hour. Real-time observation of bacterial cell co-culture visualizes the binding of antigen and antibody at the cellular level, which is convenient and time-saving, and provides a powerful tool for evaluating antibody affinity in antibody screening.
[0044] The engineered bacteria provided by the present disclosure can be specifically colonized inside the tumor, can have a tumor growth inhibitory effect to a certain extent, and has a high biosafety. Further, anticancer substances such as cytotoxic molecules are added on the basis of targeted adhesion, which can have a greater impact on the cell activity of tumor matrix cells. On the basis of targeted adhesion of engineered bacteria, anticancer substances such as clyA protein are simultaneously secreted, which can accelerate the induction of tumor cell apoptosis, destroy tumor tissue, inhibit tumor growth and produce a tumor regression effect, and have a significant anticancer effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 The results of PCR verification of 8 EcB1 single clone genomes after knockout of the fimA-H operon encoding type I fimbriae of E. coli BL21 are shown.
[0046] Figure 2 Shown is the 24-hour growth curve of EcB1 after type I pili knockout.
[0047] Figure 3 The strain morphology of EcB1 after type I pili knockout is shown.
[0048] Figure 4Shown are the results of genomic PCR validation of eight EcM1 monoclonal clones after knockout of the fimA-H operon encoding type I fimbriae of E. coli K12 MG1655.
[0049] Figure 5 Shown is the 24-hour growth curve of EcM1 after type I pili knockout.
[0050] Figure 6 The strain morphology of EcM1 after type I fimbriae knockout is shown.
[0051] Figure 7 The fluorescence confocal imaging results of EcB1 and EcM1 before and after pilus knockout are shown.
[0052] Figure 8 The results of quantification of the enrichment of EcB1 and EcM1 bacterial fluorescence intensity around individual cells before and after pili knockout are shown.
[0053] Fig. 9 It shows that both EcM1 and EcB1 express artificial synthetic adhesin (SA intimin fap or sa YeeJ fap) levels.
[0054] Fig.10 The laser scanning confocal microscope shows the different strains (E.coli BL21, EcB1, EcB1SA intimin , EcB1SA intimin fap, EcB1SA YeeJ , EcB1SA YeeJ fap) were enriched around iBCAFs and MCF-7 cells.
[0055] Fig.11 correspond Fig.10 The quantitative analysis results of the enriched bacteria around each cell in each experimental group were repeated three times, and 500 cells were counted each time).
[0056] Fig.12 The EcB1SA was observed using a laser scanning confocal microscope. intimin gfp, EcB1SA YeeJ Adhesion experiment results of gfp and EGFP positive Hela and WT Hela bacteria.
[0057] Fig.13 The three-dimensional in vivo imaging of small animals shows the colonization of bacteria in the mouse tumor site 24 hours later.
[0058] Fig.14 The distribution of bacteria in the liver, spleen, lung, heart, tumor, and tumor epithelium is shown by tissue anatomical imaging.
[0059] Fig.15 The figure shows the changes in bacterial colonization at the tumor site detected by three-dimensional in vivo imaging of small animals within 72 hours.
[0060] Fig.16 Shown are the changes in mouse tumor volume over 15 days.
[0061] Fig.17 Shown are the changes in the weight of mice with tumors within 15 days.
[0062] Fig.18 The diagram shows the dual expression pattern of SAfap and Cm recombinant proteins.
[0063] Fig.19 SAfap and Cm dual protein expression levels are shown.
[0064] Fig. 20 The change in mcherry fluorescence intensity reflects the expression level of Cm recombinant protein.
[0065] Fig.21 The mcherry fluorescence intensity in the bacterial supernatant culture medium reflects the secretion level of the Cm recombinant protein.
[0066] Fig. 22 The figure shows the apoptosis level of iBCAFs cells detected by flow cytometer after overnight treatment (16 hours) with cell culture medium without Cm recombinant protein and cell culture medium containing Cm recombinant protein.
[0067] Fig.23 The figure shows the level of apoptosis of iBCAFs cells detected by flow cytometer after treatment (4 hours) with the engineered bacteria not expressing Cm recombinant protein and the engineered bacteria expressing Cm recombinant protein.
[0068] Fig.24 Show Fig. 22 Statistical analysis results of cell activity after three biological replicate experiments.
[0069] Fig.25 Show Fig.23 Statistical analysis results of cell activity after three biological replicate experiments.
[0070] Fig.26 The figure shows the colonization of bacteria in the mouse tumor site 24 hours after small animal three-dimensional in vivo imaging detection.
[0071] Fig. 27 The distribution of bacteria in the liver, spleen, lung, heart, tumor, and tumor epithelium is shown by tissue anatomical imaging.
[0072] Fig.28 The changes in tumor volume of mice within 15 days are shown.
[0073] Fig.29 Shown are the changes in mouse body weight over 15 days.
[0074] Fig.30 Hematoxylin and eosin staining of tumor sections is shown, and white arrows indicate the tumor tissue sites destroyed by the engineered bacteria.
[0075] Fig.31 Immunohistochemical staining of tumor sections is shown, and the black arrows indicate the tumor tissue sites destroyed by the engineered bacteria. DETAILED DESCRIPTION
[0076] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with embodiments. The specific embodiments described herein are only used to explain the present invention and are not intended to constitute any limitation of the present invention. In addition, in the following description, the description of known structures and technologies is omitted to avoid unnecessary confusion of the concepts of the present disclosure. Such structures and technologies are also described in many publications.
[0077] The engineered bacteria provided by the present disclosure have had their pili knocked out, which can significantly reduce the non-specific adhesion rate. The expression vector used: pET28a SA intimin and pET28aSA YeeJ It is a single-domain antibody display platform that efficiently induces expression on the surface of bacteria. The FAP single-domain antibody display system on the surface of engineered bacteria and its own tumor targeting and colonization ability can achieve specific targeting and colonization of FAP+CAFs, solving the problem of effectively eliminating the tumor-promoting function of CAFs and continuously activating the anti-tumor immune response in the body. By replacing the single-domain antibody part in the surface display system of engineered bacteria, specific targeting of different target cells can be achieved. The preparation and production of engineered bacteria only requires the culture medium required for their growth, and 0-4°C can inhibit growth and preserve them, solving the cost problem.
[0078] In a specific embodiment, the engineered Escherichia coli disclosed herein displays a FAP single-domain antibody on the surface, which can achieve tumor-targeted colonization, thereby achieving specific targeting of the FAP antigen on CAF cells and colonization in the tumor microenvironment, effectively eliminating the tumor-promoting function of CAFs and continuously activating the anti-tumor immune response in vivo.
[0079] The present invention constructs a mouse cancer model and verifies that the provided engineered bacteria can specifically colonize inside the tumor in the mouse body, has a tumor growth inhibitory effect, and has no effect on the growth of the mouse.
[0080] In a specific embodiment of the present disclosure, clyA cytotoxic molecules were added on the basis of targeted adhesion, so that the adhesion factor-FAP single domain antibody and the cytotoxic molecules were co-expressed and used in a mouse cancer model. The results showed that the engineered bacteria targetedly adhered around cancer cells and secreted clyA protein to accelerate the induction of cell apoptosis.
[0081] definition
[0082] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly used in the field to which the present invention belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa.
[0083] As used herein, the articles "a," "an," and "an" include plural referents unless the context clearly dictates otherwise.
[0084] The expression "about" as used herein is understood by one of ordinary skill in the art and varies within a certain range depending on the context in which it is used. If one of ordinary skill in the art is not aware of the use of the term based on the context in which it is used, "about" will mean up to plus or minus 10% of the specified value.
[0085] As used herein, the term "fusion protein" refers to a polypeptide or protein comprising two or more subunits. In some embodiments, the fusion protein described herein comprises two or more subunits, which may be linked by covalent or non-covalent bonds. Preferably, the fusion protein is a translational fusion between two or more subunits. The translational fusion can be produced by genetically engineering the coding sequence of one subunit in frame with the coding sequence of another subunit.
[0086] The term "fimbrial" as used herein describes a sensory and motor device that has evolved specifically for bacterial movement. Type I pili are hair-like protein protrusions on the surface of most Gram-negative bacteria and a few Gram-positive bacteria. Taking Escherichia coli (E. coli) as an example, type I pili are encoded by the fimA-H operon. The fimA-H operon coding sequence is 8754bp in length, including two transcriptional regulatory genes, fimB and fimE, four structural genes, fimA, fimE, fimG and fimH, and the fimC and fimD genes responsible for encoding chaperone proteins and guide proteins, respectively. Type I pili play an important role in bacterial adhesion, colonization and biofilm formation. The apical adhesin encoded by the fimH gene is exposed to the bacterial surface, can recognize various mammalian cell surface mannosylated receptor proteins, and is also a key gene and virulence factor for Escherichia coli biofilm formation. In some embodiments of the present disclosure, the non-specific adhesion problem of most engineering bacteria is solved by knocking out the engineering bacteria of natural type I pili.
[0087] The term "autotransporter" as used herein is a class of proteins that are widely present in Gram-negative bacteria, usually as an outer membrane protein or secretory protein of bacteria, and plays an important role in the various life activities of bacteria. Autotransporters are generally composed of a signal peptide, an N-terminal passenger domain and a C-terminal transmembrane domain (also known as a β-barreled domain). Depending on the difference in the transmembrane domain, autotransporters can be divided into 5 types: Va, Vb, Vc, Vd and Ve. Among them, the Ve type has a reverse structure, with its N-terminal being a transmembrane domain and its C-terminal being a passenger domain.
[0088] The term "cancer-associated fibroblast (CAF)" or "tumor-associated fibroblast" as used herein refers to a cell that is activated by transformation of normal fibroblasts, bone marrow mesenchymal cells, epithelial cells, endothelial cells, adipocytes, pericytes, stellate cells, etc., which are originally present in the tumor site and are affected by the tumor microenvironment (TME). CAFs can regulate the structure and / or function of the TME, for example, by remodeling the extracellular matrix (ECM) and / or the secretion of soluble factors (e.g., growth factors and / or inflammatory factors). CAFs may contribute to tumorigenesis, tumor growth, tumor invasion, angiogenesis, or metastasis. CAFs may impair anti-tumor immunity.
[0089] The term "fibroblast activated protein (FAP)" used in this article is generally a membrane-integrated glycoprotein present on activated fibroblasts, belongs to the serine protease family, has 52% homology with dipeptidyl peptidase IV (DPP IV), a member of the dipeptidyl peptidase family, has both dipeptidyl peptidase and collagenase activities, and can cleave the connection between amino acids at the carbon end of proline.
[0090] The term "tumor" as used herein refers to a mass or neoplasm, which itself is defined as an abnormal new growth of cells that usually grow faster than normal cells and will continue to grow if not treated, sometimes causing damage to adjacent structures. Tumors can vary greatly in size. Tumors can be solid or fluid-filled. Tumors can refer to benign (non-malignant, usually harmless) or malignant (capable of metastasizing) growths. Some tumors may contain benign neoplastic cells (e.g., carcinoma in situ) while also containing malignant cancer cells (e.g., adenocarcinoma). It should be understood to include neoplasms located in multiple locations throughout the body. Therefore, for the purposes of this disclosure, tumors include primary tumors and metastatic tumors.
[0091] The term "cancer" as used herein refers to a disease or disorder caused by proliferation of cells that are oncogenically transformed. "Cancer" shall include any one or more of a wide range of benign or malignant tumors, including those tumors that are capable of invasive growth and metastasis through the human or animal body or parts thereof, such as via the lymphatic system and / or bloodstream. Although the present invention is particularly intended to diagnose or detect malignant tumors and solid cancers, as used herein, the term "tumor" includes both benign and malignant tumors or solid masses. Examples of cancer include, but are not limited to, solid tumors, hematological tumors, lymphomas (e.g., Hodgkin's lymphoma and non-Hodgkin's lymphoma), blastomas, sarcomas, e.g., squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, hepatocellular carcinoma, gastrointestinal cancer, pancreatic cancer, gliomas, cervical cancer, ovarian cancer, bladder cancer, liver cancer, breast cancer, colon cancer, colorectal cancer, endometrial cancer or uterine cancer, peritoneal cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, hepatocellular carcinoma, leukemias and other lymphoproliferative disorders, and various types of head and neck cancer.
[0092] As used herein, the term "cancer cell" is a mutated cell that is the source of cancer. Cancer cells are different from normal cells in that they have three characteristics: unlimited proliferation, transformation, and easy metastasis. They can proliferate indefinitely and destroy normal cell tissues. In addition to uncontrolled division (can divide indefinitely), cancer cells can also locally invade surrounding normal tissues and even metastasize to other parts of the body through the body's circulatory system or lymphatic system.
[0093] As used herein, the term "tumor stromal cells (Cancer-associated fibroblasts, CAF)" refers to a cell population present in the tumor microenvironment, which plays an important regulatory and supportive role. CAF cells can be divided into different subtypes according to their origin, function and expression characteristics, such as the expression of specific cytokines, signaling pathways and cell markers.
[0094] As used herein, the term "operably connected" represents a physical or functional connection between two or more elements (e.g., a polypeptide sequence or a polynucleotide sequence) that allows them to operate in the manner they expect. For example, when used in the context of a coding sequence and a promoter sequence in a nucleic acid molecule as described herein or a nucleic acid molecule, the term "operably connected" means that the coding sequence and the promoter sequence are in frame, and in an appropriate space and distance, to allow each combination of a transcription factor or RNA polymerase to exert an influence on transcription. It should be understood that the elements that are operably connected can be continuous or discontinuous (e.g., connected to each other by a joint). In the context of a polypeptide construct, "operably connected" refers to a physical connection (e.g., directly or indirectly connected) between an amino acid sequence (e.g., different sections, parts, regions or domains) to provide the described activity of a construct. The sections, parts, regions and domains that are operably connected of a polypeptide or a nucleic acid molecule disclosed herein can be continuous or discontinuous (e.g., connected to each other by a joint).
[0095] The term "linker" as used herein refers to a (peptide) linker of natural and / or synthetic origin, composed of linear amino acids. The domains in the bispecific fusion polypeptide of the present invention can be connected by a linker, wherein each linker is fused to at least two polypeptides or domains and / or connected in other ways (e.g., via a peptide bond). The classification of linkers is, for example, flexible linkers, rigid linkers, etc. "Rigid linkers" are composed of amino acid residues that are easy to form a stable secondary structure. In many cases, because they can form a relatively stable secondary structure, they can more effectively separate the functional domains and maintain their independent functions than flexible linkers. When the space for separating the functional domains is crucial to the stability and biological activity of the fusion protein, a rigid linker can be selected. Many natural rigid linkers form an alpha helical structure. The commonly used rigid alpha helical linker is (EAAAK)n (n≤6). Due to the presence of hydrogen bonds inside it and a compact skeleton, the alpha helical structure is rigid and stable. "Flexible linkers" are composed of small non-polar amino acids (such as glycine) or polar amino acids (such as serine or threonine). Small amino acids can provide more flexibility, so that the connected functional domains do not interfere with each other and thus play their roles better. Polar amino acids such as serine and threonine can form hydrogen bonds with water molecules, thus ensuring the stability of the linker in aqueous solution while reducing adverse reactions between the linker and the protein region.
[0096] The linker should have a length suitable for connecting two or more domains, and the linker can ensure that the different domains connected to it are correctly folded and appropriately presented, so as to exert their biologically active functions. In different embodiments, the linker has a flexible conformation. Suitable flexible linkers include, for example, glycine, glutamine and / or serine residues. In some embodiments, the linker can be selected from (GnS)m, (G)n, (EAAAK)n or (XP)n, wherein n and m are each independently selected from integers of 0 to 5. For example, n is selected from 0, 1, 2, 3, 4 or 5, and m is selected from 1, 2, 3, 4 or 5.
[0097] The term "antibody" as used herein is a polypeptide substantially encoded by one immunoglobulin gene or multiple immunoglobulin genes or fragments thereof in nature, which specifically binds and recognizes an analyte (e.g., an antigen or immunogen), such as an RSV F protein or an antigenic fragment thereof. Immunoglobulin genes include kappa, lambda, alpha, gamma, 6, epsilon, and mu constant region genes, as well as numerous immunoglobulin variable region genes. The term "antibody" as used herein includes antibody fragments produced, for example, by modification of intact antibodies and by de novo synthesis using recombinant DNA methods.
[0098] As used herein, the terms "antigen-binding fragment," "fragment," and "antibody fragment" are used interchangeably and refer to any fragment of an antibody of the present invention that retains the antigen-binding activity of the antibody. Examples of antibody fragments include, but are not limited to, single-chain antibodies, Fab, Fab', F(ab')2, Fv, or scFv. Further, as used herein, the term "antibody" includes both antibodies and antigen-binding fragments thereof.
[0099] As used herein, the term "operon" refers to a functional unit of DNA containing a cluster of genes controlled by a single regulatory signal or promoter. Operators are common in prokaryotes, such as bacteria, where they can effectively regulate gene expression.
[0100] As used herein, the term "sequence identity" refers to the "percentage of sequence identity" or "percentage of sequence identity" between two polynucleotides, i.e., the number of identical matching positions shared by the sequences within a comparison window, taking into account additions or deletions (i.e., gaps) that must be introduced for optimal alignment of the two sequences. A matching position is any position where the same nucleotide is present in both the target sequence and the reference sequence. Since a gap is not a nucleotide, a gap present in the target sequence is not counted. Likewise, since the target sequence nucleotides are counted and the nucleotides from the reference sequence are not counted, gaps present in the reference sequence are not counted. At least 60% sequence identity includes a contiguous segment having at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity over the entire length of the sequence.
[0101] The sequence identity percentage can be calculated by the following process: determine the number of positions where the same amino acid residue or nucleic acid base occurs in both sequences to obtain the number of matching positions, divide the number of matching positions by the total number of positions in the comparison window, and multiply the result by 100 to obtain the sequence identity percentage. The determination of the sequence identity percentage between the comparison of the sequence and the two sequences can be completed using software that is easy to use and download online. Suitable software programs can be obtained from various sources for the comparison of protein and nucleotide sequences. A suitable program for determining the sequence identity percentage is bl2seq, which is a part of the BLAST program suite that can be obtained from the BLAST website (blast.ncbi.nlm.nih.gov) of the National Center for Biotechnology Information of the U.S. Government. Bl2seq uses BLASTN or BLASTP algorithms to compare between two sequences. BLASTN is used for comparing nucleic acid sequences, and BLASTP is used for comparing amino acid sequences. Other suitable programs are, for example, Needle, Stretcher, Water or Matcher, part of the EMBOSS suite of bioinformatics programs and also available from the European Bioinformatics Institute (EBI) at www.ebi.ac.uk / Tools / psa.
[0102] The term "cell adhesion" as used herein refers to the adhesion of one or more cells to the surface of another cell by any force, such as cell adhesion that occurs through the specific binding of an antibody on the surface of a cell to an antigen on the surface of another cell.
[0103] Examples and drawings are provided below to help understand the present invention. However, it should be understood that these examples and drawings are only used to illustrate the present invention, but do not constitute any limitation. The actual protection scope of the present invention is set forth in the claims. It should be understood that any modifications and changes can be made without departing from the spirit of the present invention.
[0104] Example
[0105] Example 1. Knockout of the fimA-H operon in E. coli BL21
[0106] In order to solve the problem of non-specific adhesion of E. coli, we knocked out the type I pili encoded by the fimA-H operon based on E. coli BL21 (DE3) to reduce the probability of non-specific adhesion of the engineered bacteria. The E. coli BL21 mutant lacking the fimA-H operon was named EcB1.
[0107] Specifically, the CRISPR / Cas gene editing system (pCas9 and pTarget2N20) was used to knock out the fimA-H operon of E. coli BL21 (DE3), and the steps are as follows:
[0108] 1. Design sgRNA sequences targeting fimB and fimH genes respectively:
[0109] fimB sgRNA1 N20_F: 5'-CATATTATCTCGACTTCCGG-3' (SEQ ID NO: 15);
[0110] fimB sgRNA1 N20_R: 5'-CCGGAAGTCGAGATAATATG-3' (SEQ ID NO: 16);
[0111] fimH sgRNA2 N20_F: 5'-GACTATGTCACACTGCAACG-3' (SEQ ID NO: 17);
[0112] fimH sgRNA2 N20_R: 5'-CGTTGCAGTGTGACATAGTC-3' (SEQ ID NO: 18).
[0113] The pTarget2N20 plasmid was constructed using sgRNA1 and sgRNA2, and a 1 kb Donor fragment consisting of about 500 bp on both sides of the fimA-H operon was synthesized.
[0114] 500 bp upstream of fimA-H operon (5'-3'):
[0115] catggcgtaagctgacgaatcagcaggaataatcgctagggacctaagaattagcatgataatagccactaagaaattactgcgctccatgaaatagccattttgtggcaaatggagttgactaataatgtcatatgtgagacggctagttgaacgaatattaaattttgctgaattttttatgttgattttacttgttacagaacatatcacatgatatatagataagattagttgcattaatgatgagggttattattagattcgtatccgattgataaatatataaaggtacatagcatgcaagagcatggcgtttgtatggcaacgttattataattaacagttgctactccatttaagttcactcagaagaactggtccacttacgttagttattaagcaaacgttcgcttttataaacataatcaggataaaaatgttggattattgctaacccagcacagctagtgcgcgtctgtaattataagggaaaaacg(SEQ ID NO: 19)
[0116] 500 bp downstream of the fimA-H operon (5'-3'):
[0117] agaaatcacaggacattgctaatgctggtacgcaatattacctgaagctaaaaacctgcacgttagccctttgtaggccagataagacgcgtcagcgtcgcatctggcataaacaaagcgcacttt gctggtctgttcccctcaccctaaccctctccccggaggggcgaggggactgtccgggcacatttttagactttgtcatcagtctgagcctgccattggcaggctctggtgtccttttacgctacc atgctaataatcagcacaataatcagcccaaccacggagttgaccagctccagcagaccccaggttttcaacgtgtcttttactgacaggtcaaagtaacctttgaacaaccagaaagatgcatcg ttaatgtgggtgagggtgttggaacccgcagccgtcgccagtaccagcagcgccggattcacgccaaccagctgaccagttgctggatctaggattgcagcactgataatcccggcggcggt(SEQ ID NO:20)
[0118] 2. The pTarget2N20 and Donor fragments were simultaneously transformed into E.coliBL21::pCas9 competent cells expressing Cas9 protein. Cells in which the fimA-H operon coding sequence had been successfully knocked out were obtained, namely the type I pili mutant strain EcB1::pCas9::pTarget2N20 (abbreviated as EcB1). The mutant cells obtained were subjected to genomic PCR using the following primers.
[0119] Primer A: ATCAGTGTTTACCCGCCATC (SEQ ID NO: 21)
[0120] Primer B: CGATTTCACTATGGGTCAGGA (SEQ ID NO: 22)
[0121] Primer C: CTGGTTCAGTGCCAATTCCT (SEQ ID NO: 23)
[0122] Primer D: TGCTGAAGCAGACCATCATC (SEQ ID NO: 24)
[0123] Primer A and primer D target the upstream and downstream of the Donor fragment, respectively, primer B targets the fimB gene fragment, and primer C targets the fimH gene fragment. The PCR verification results are as follows Figure 1 As shown, lanes 1 to 8 are 8 clones of type I pilus mutant strain EcB1, and lane BL is the genome PCR result of BL21, wherein the Sanger sequencing nucleotide sequence of the amplification product of primers A and D is shown in SEQ ID NO: 25.
[0124] Figure 2 Shown are 24-hour growth curve assays of BL21 and mutant strain EcB1. Figure 3 The morphological observation diagram of BL21 and mutant strain EcB1 is shown ( Figure 3 The results showed that the loss of type I pili had no significant effect on the growth and morphology of EcB1.
[0125] Example 2. Knockout of the fimA-H operon in E. coli K12 MG1655
[0126] This example also uses the CRISPR / Cas gene editing system (pCas9 and pTarget2N20) to knock out the fimA-H operon encoding type I fimbriae in the E. coli K12MG1655 genome (sgRNA and Donor fragments are the same as EcB1), and the knockout strain is named EcM1.
[0127] Genomic PCR verification (primers are the same as EcB1), the results are as follows Figure 4 The PCR results of the genomes of six EcM1 monoclonal strains are shown in FIG. MG is the PCR result of the genome of E. coli K12 MG1655. The Sanger sequencing nucleotide sequence of the amplification product of primers A and D is shown in SEQ ID NO: 26.
[0128] The 24-hour growth curves of EcM1 and E.coli K12 MG1655 were observed ( Figure 5 ) and strain morphology observation results ( Figure 6 The results showed that the loss of type I pili had no significant effect on the growth and morphology of EcM1.
[0129] Example 3. Detection of the effect of the loss of type I pili on nonspecific cell adhesion
[0130] The specific adhesion efficiency of the engineered bacteria was verified by co-culture of bacterial cells.
[0131] Place an 8 mm cell slide in a 24-well plate and seed 2 × 10 5 iBCAF breast cancer associated fibroblasts (FAP-positive cell line) and 4×105 Human breast cancer cell MCF-7 cells (FAP negative cell line). The type I pili-deficient engineered bacteria EcM1 and EcB1 obtained in Example 1 and Example 2 were respectively cultured at 1-2×10 8 CFU / mL concentration was resuspended in 50 μL of E. coli serotype O / K polyclonal antibody (1:1000, Invitrogen) and incubated at room temperature for 45 minutes. Centrifuge again and rinse twice with PBS. Resuspend with 50 μL of Cy3-conjugated secondary antibody (1:500, ABclonal) and incubate at room temperature in the dark for 45 minutes. Centrifuge, rinse twice with 100 μL PBS, and resuspend the bacterial pellet in fresh cell culture medium at a final concentration of 6×10 7 CFU / mL. 1 mL of bacterial suspension was added to each well of a 24-well plate containing cells, with an MOI of 300:1. After infection at 37°C for 1 hour, the cells were rinsed 5 times with PBS. Fix with 300 μL 4% PFA for 15 minutes at room temperature. Rinse twice with PBS, then stain the nuclei with 1 μg / mL DAPI for 20 minutes, and then gently mount the cell slides onto clean glass slides with anti-fading mounting medium. The bacteria enriched around the cells were examined using a fluorescence microscope and quantified using an imaging analysis system. The results are shown in Figure 7 and Figure 8 middle.
[0132] like Figure 7 and Figure 8 As shown, knockout of fimA-H encoding type I fimbriae significantly reduced the nonspecific adhesion of EcM1 and EcB1 to cells.
[0133] Example 4. Artificially synthesized adhesins expressing fusion of FAP single domain antibody and GFP single domain antibody on the surface of EcB1 and EcM1
[0134] In order to give EcB1 and EcM1 specific targeting function, we tried to express artificial synthetic adhesins fused with FAP single-domain antibodies on the surface of EcB1 and EcM1, and also constructed artificial synthetic adhesins fused with green fluorescent protein GFP single-domain antibodies as a control (the amino acid sequence of FAP single-domain antibody is shown in SEQ ID NO: 7, and the GFP single-domain antibody sequence is derived from Xiong Z, et al. Elife. 2021; 10: e64631).
[0135] Two transmembrane domains of bacterial surface adhesins were selected as antibody display platforms: (1) Intimin (659 amino acids, amino acid sequence as shown in SEQ ID NO: 1), a tight adhesin from enterohemorrhagic Escherichia coli (EHEC), contains a signal peptide, an N-terminal lysozyme motif (LysM) located in the periplasm, a transmembrane β-barrel domain, and a conserved domain D0 at the C-terminus. (2) Intimin-like adhesin YeeJ (515 amino acids, amino acid sequence as shown in SEQ ID NO: 2), derived from wild-type Escherichia coli E. coli MG1655, also contains a signal peptide, an N-terminal lysozyme motif (LysM) located in the periplasm, a transmembrane β-barrel domain, and a C-terminal linker domain as a conserved domain.
[0136] At the C-terminus of intimin or YeeJ, a V5 tag (SEQ ID NO: 12, located between Hind III and Nhe I restriction sites), a 6×His tag (SEQ ID NO: 13, located between Nhe I and BamH I restriction sites) and a c-myc tag sequence (SEQ ID NO: 14) were sequentially fused, and a FAP single-domain antibody sequence or a GFP single-domain antibody sequence was fused at the N-terminus.
[0137] Nucleic acid sequences encoding intimin (SEQ ID NO: 1), YeeJ (SEQ ID NO: 2), intimin-FAP single domain antibody (SEQ ID NO: 3), YeeJ-FAP single domain antibody (SEQ ID NO: 4), intimin-GFP single domain antibody (SEQ ID NO: 5) and YeeJ-GFP single domain antibody (SEQ ID NO: 6) were synthesized and constructed into the pET28a+ vector to obtain expression vectors pET28a-intimin, pET28a-YeeJ, pET28a-intimin-FAP, pET28a-YeeJ-FAP, pET28a-intimin-GFP and pET28a-YeeJ-GFP, respectively. The constructed expression vector was electroporated into EcB1 competent cells and EcM1 competent cells respectively. After overnight culture, the obtained single clone was transferred to fresh LB medium at a ratio of 1:100 and cultured at 37°C until OD = 0.7. 0.05 mM IPTG (isopropyl-β-d-thiogalactoside) was added and induced for expression at 37°C for 8 to 16 hours. V5 tag antibody was co-incubated with appropriate amount of bacteria for flow cytometry detection to verify the synthetic adhesin (SA) intimin ,SA intiminfap, SA intimin GFP, SA YeeJ ,SA YeeJ fap and SA intimin The GFP level was successfully expressed in EcM1 and EcB1. The results are shown in Fig. 9 The engineered bacteria expressing synthetic adhesin (SA) were named EcB1SA intimin fap, EcB1SA YeeJ fap, EcB1SA intimin GFP and EcB1SA YeeJ gfp.
[0138] Example 5. Adhesion experiment of engineered bacteria specifically targeting cancer-associated fibroblasts
[0139] According to a method similar to Example 3, the engineered bacteria EcB1SA was verified by co-culturing bacterial cells. intimin , EcB1SA intimin fap, EcB1SA YeeJ , EcB1SA YeeJ Specific adhesion efficiency of FAP to iBCAF breast cancer associated fibroblasts (FAP positive cell line) and MCF-7 cells (FAP negative cell line).
[0140] The enrichment of bacteria around cells was observed under a fluorescence microscope and the bacteria enriched around cells were quantitatively analyzed using an imaging analysis system. The results are shown in Fig.10 and Fig.11 middle.
[0141] like Fig.10 and Fig.11 As shown, it can be seen that EcB1SA intimin fap, EcB1SA YeeJ fap was highly enriched around iBCAF cells. However, there were only a few engineered bacteria around MCF-7 cells, and EcB1 significantly reduced non-specific adhesion compared to E.coli BL21. intimin , EcB1SA YeeJ The probability of non-specific adhesion is increased due to the absence of the FAP single domain antibody. From the observation results and quantitative analysis results, it can be concluded that the artificial adhesin fused with the single domain antibody can give the engineered bacteria the ability to specifically target and adhere to the target cells.
[0142] Example 6. Adhesion experiment of engineered bacteria specifically targeting EGFP
[0143] According to the method similar to Example 4, the coding nucleotide sequence of enhanced green fluorescent protein EGFP was inserted into the pDisplay vector (Miaoling Biotechnology) to construct the pDisplay EGFP plasmid. Hela cells were transfected with the pDisplay EGFP plasmid to express GFP (SEQ ID NO: 11) on the cell membrane surface, and then EcB1SA intimin gfp, EcB1SA YeeJ gfp was co-cultured with cell membrane GFP-positive Hela and WT Hela at 37°C for 1 hour. The specific adhesion efficiency of the engineered bacteria and was verified by co-culture of bacterial cells in a similar manner to Example 3, and observed by laser scanning confocal microscopy. The results are shown in Fig.12 middle.
[0144] like Fig.12 As shown, EcB1SA can be observed intimin gfp, EcB1SA YeeJ GFP was highly enriched around GFP-positive Hela cells at the cell membrane, but only a few bacteria were found around WT Hela cells.
[0145] Example 7. In vivo verification of engineered bacteria specifically targeting tumor colonization
[0146] First, the MC38 cell line (mouse colon adenocarcinoma cell line) was used to construct a colon adenocarcinoma model. The specific method is as follows:
[0147] 1. Collect and count MC38 cells, wash once with pre-cooled PBS, and centrifuge at 300g for 5 minutes.
[0148] 2. Take several 1.5 mL centrifuge tubes and add 50 μL Matrigel to each centrifuge tube.
[0149] 3. Gently resuspend the cells obtained in step 1 with 2 mL PBS and dispense into centrifuge tubes containing 50 μL Matrigel, with 50 μL MC38 cells (about 1×10 6 ), and gently pipette to mix to obtain a 100 μL mixed solution of Matrigel and MC38.
[0150] 4. Use a disposable sterile insulin syringe to gently draw 100 μL of Matrigel and MC38 mixture and inject it subcutaneously into the right back of C56BL / 6N mice of about 8 weeks old (the number of MC38 cells injected per mouse is 1×10 6 ).
[0151] 5. Observe the tumor formation of mice regularly every day. After about 7 to 9 days, the tumor volume reaches 200 to 300 mm 3After (tumor volume = 0.5 × length × width 2 ), and the tumor-bearing mice were randomly divided into groups for subsequent experiments.
[0152] The bacteria were injected into MC38 tumor-bearing mice through the tail vein, and the distribution of engineered bacteria in tumor-bearing mice was detected using a small animal three-dimensional in vivo imaging device to test the tumor-targeting colonization ability of engineered bacteria in vivo. The specific experimental methods are as follows:
[0153] 1. Prepare E.coli BL21, EcB1, and EcB1SA respectively intimin , EcB1SA intimin fap fresh bacterial culture medium.
[0154] 2. Take 1 mL of bacterial solution with OD600 = 1, centrifuge at 5000 rpm for 2 min, and wash the bacteria twice with PBS.
[0155] 3. Add 100 μL PBS to resuspend the cells, add 2 μL 1 mg / mL Dir dye (Bidec Pharmaceuticals), mix well, and incubate at room temperature in the dark for 1 hour.
[0156] 4. Centrifuge at 5000 rpm for 2 min. Wash the cells twice with PBS.
[0157] 5. Resuspend the bacteria in 1 mL PBS. The tail vein injection volume of each tumor-bearing mouse is 100 μL of bacterial solution (CFU = 1×10 8 ).
[0158] 6. 24 hours after bacterial injection, the mice were imaged in vivo to detect the distribution of bacteria in the body.
[0159] 7. Within 15 days after bacterial injection, the tumor volume and body weight of the mice were measured and recorded at a fixed time every day. During the experiment, 1M IPTG was added to the drinking water of the mice to continuously induce the engineered bacteria to express artificially synthesized adhesins.
[0160] The results are as follows Figures 13 to 17 shown.
[0161] Fig.13 24 hours after the tail vein injection of bacterial solution, the distribution of bacteria in tumor-bearing mice in each experimental group was detected using a small animal in vivo imaging system. Some E. coli BL21 can escape into the tumor naturally to avoid the attack of the immune system. However, the adhesion ability of EcB1 without natural type I pili is greatly reduced, and it is easily affected by the metabolism of mice and accumulates in the liver. EcB1SA intimin Due to the expression of exogenous tight adhesion protein intimin, some adhesion ability is restored, a small part can escape to the tumor site, and most of it is metabolized and accumulated by the kidney. intiminThe fap strain targeted and colonized the tumor site in large quantities.
[0162] Fig.14 for Fig.13 EcB1SA intimin and EcB1SA intimin Results of dissecting and imaging the various tissues of mice 24 hours after injection of fap engineered bacteria. intimin and EcB1SA intimin FAP accumulates in the liver and spleen, which may be due to the liver and spleen removing metabolic waste and toxic substances from the body. intimin In comparison, EcB1SA intimin FAP can be localized to the tumor cortex, which is the tumor protective barrier formed by the tumor stromal cells on the outer layer of the tumor.
[0163] Fig.15 EcB1SA for 72 hours intimin and EcB1SA intimin Dynamic changes in the distribution of FAP in tumors. intimin and EcB1SA intimin fap can quickly locate the tumor site within 4 hours, but EcB1SA changes over time intimin The enrichment in mouse tumors gradually decreased, while EcB1SA intimin FAP can be continuously colonized in the tumor site in large quantities due to the support of the FAP antigen-antibody binding effect. intimin The enrichment level of EcB1SA in mouse tumors was significantly lower than that at 4 h. intimin The enrichment of FAP in mouse tumors did not change significantly from 4h to 72h, and always maintained a high enrichment level.
[0164] Fig.16 The changes in tumor volume of tumor-bearing mice were measured over 15 days. intimin The tumor growth of the tumor-bearing mice in the fap experimental group was relatively stable and the tumor volume was the smallest after 15 days, proving that the engineered bacteria EcB1SA intimin The colonization of fap in mouse tumors can inhibit tumor growth to a certain extent. intimin Without FAP antibody surface display, the colonization persistence in the tumor site is not strong. Although the tumor volume decreased on the 9th day, showing a certain tumor suppression effect, the tumor volume began to rise linearly after the 11th day. E.coli BL21 and EcB1 have similar effects on the growth of tumor volume.
[0165] Fig.17 The weight changes of tumor-bearing mice were measured within 15 days. The weight of mice in each group showed an increasing trend, proving that tail vein injection of E.coli BL21, EcB1, and EcB1SA intimin and EcB1SA intimin fap had no effect on the growth of mice. intimin The body weight of fap mice was maintained at a higher level, indicating that EcB1SA intimin fap has high biosafety.
[0166] Example 8. Engineering bacteria secrete therapeutic factor (ClyA) to inhibit tumor growth
[0167] Cytolysin A (ClyA) is a cytotoxic protein that can form pores on the cell surface. It can be secreted by a variety of Escherichia coli or Salmonella through outer membrane vesicles (OMVs) without modification of signal peptides. At high concentrations, ClyA can induce cell lysis, while at low concentrations, ClyA can affect intracellular signal transduction. Because ClyA can be expressed on the surface of bacteria or bacterial secreted OMVs as an antigen to cause immune response, it is also used in vaccine development and anti-tumor drug research.
[0168] This example studies the simultaneous secretion of ClyA to induce apoptosis of target cells based on the targeted target cells of engineered bacteria. The protein dual expression plasmid pETDuet-SAfap-Cm was constructed based on the pET28-SAfap plasmid in Example 2. Fig.18 As shown in the example, two T7 promoters are used to regulate the expression of SAfap protein and ClyA-mcherry (Cm) fusion protein respectively. ClyA-mcherry fusion protein (Cm, SEQ ID NO: 10) is obtained by fusion expression of ClyA recombinant protein (SEQ ID NO: 8) and mcherry fluorescent protein (SEQ ID NO: 9), so that the engineered bacteria have red fluorescence, and the fluorescence intensity of mchery can also reflect the expression and secretion of ClyA.
[0169] pETDuet-SA intimin fap-Cm and pETDuet-SA YeeJ fap-Cm two protein dual expression plasmids were transformed into EcB1 electroporation competent cells to obtain EcB1SA intimin fapCm、EcB1SA YeeJ fapCm two strains. After IPTG induction, the OD of the bacterial solution was measured 600 , press 1OD600 =1×10 9 , take 0.5OD bacterial solution, centrifuge and wash twice with PBS, add appropriate amount of V5 tag monoclonal antibody diluted with PBS, AlexaFluor TM 647 (Invitrogen), incubate on ice for 45 min, discard the supernatant after centrifugation, add PBS to wash twice, and finally add 400 μL PBS to resuspend the cell pellet. Select the fluorescence signal detection channel corresponding to the V5 tag antibody and mcherry in the flow cytometer to detect the expression of SA and Cm in the same strain, EcB1 and EcB1SA intimin fap and EcB1SA YeeJ The fap strain was used as a negative control. The results are shown in Fig.19 middle.
[0170] like Fig.19 As shown, EcB1SA intimin fap and EcB1SA YeeJ The fap strain does not express Cm protein, but expresses SA at high levels intimin fap and SA YeeJ fap;EcB1SA intimin fapCm and EcB1SA YeeJ fapCm strains also express SA at high levels intimin / YeeJ fap and Cm proteins. EcB1SA intimin Induction of SA in fapCm intimin The amount of bacteria with dual expression of fap and Cm proteins can reach 82%.
[0171] Next, pick the above EcB1SA intimin fapCm and EcB1SA YeeJ The fapCm strain monoclone was cultured at 37°C and 220rpm for 12 to 16 hours. At a ratio of 1:100, the overnight culture was transferred to fresh liquid culture medium, and cultured at 37°C and 220rpm for 2 to 2.5 hours. When OD600≈0.7, 0.05mM IPTG was added, mixed thoroughly with the bacterial solution, and then dispensed into a black 96-well plate. Three wells were set for each strain monoclone, and 120μL of bacterial solution was added to each well. The detection program was preset in the high-throughput detector: the mcherry fluorescence intensity was recorded every 10 minutes from the bottom of the 96-well plate, and the culture temperature and trajectory oscillation culture mode were set to 37°C for a total of 16 hours. The results are shown in Fig. 20 middle.
[0172] Fig. 20 The results of real-time monitoring of mcherry fluorescence intensity changes using a high-throughput screening detector are shown. intiminfapCm and EcB1SA YeeJ Dynamic results of Cm protein expression in fapCm strain. intimin fapCm and EcB1SA YeeJ The fapCm strain expressed Cm at a high level under the induction of IPTG. The expression level increased exponentially within 4 hours and remained stable for 4 to 16 hours. intimin fapCm and EcB1SA YeeJ The fapCm strain will show background expression of Cm, but the expression level is low.
[0173] Fig.21 Shows Fig. 20 The fluorescence intensity of mcherry in the corresponding bacterial culture supernatant. The results show the extracellular secretion of Cm. Under IPTG induction, EcB1SA intimin fapCm and EcB1SA YeeJ The fluorescence intensity of mcherry in fapCm bacterial culture medium is much higher than that without IPTG induction. intimin fapCm and EcB1SA YeeJ The fapCm strain was able to simultaneously express SAfap and Cm at high levels under IPTG induction conditions and successfully secrete Cm into the extracellular space.
[0174] The induction of apoptosis by Cm recombinant protein and EcB1SA-fap-Cm engineered bacteria was tested in vitro. Briefly, the supernatant of the culture medium containing Cm and EcB1SAfapCm bacteria was incubated with iBCAFs cells. The cells treated with LB medium were used as the control group, and iBCAFs were incubated with EcB1SA-fap-Cm without Cm recombinant protein. intimin fap, EcB1SA YeeJ fap strain culture supernatant, containing Cm recombinant protein EcB1SA intimin fapCm and EcB1SA YeeJ fapCm strain culture supernatant was incubated overnight for 12 to 16 hours. The survival of iBCAFs cells was detected by flow cytometry after staining with Annexin V-APC / PI cell apoptosis detection kit (Vazyme). The results are shown in Fig. 22 The statistical analysis results of cell activity after three biological replicates are shown in Fig.24 middle.
[0175] like Fig. 22 and Fig.24 As shown, EcB1SA containing Cm recombinant protein intimin fapCm and EcB1SAYeeJ The apoptosis rates of iBCAFs cells incubated overnight with the supernatant of the fapCm strain culture medium were approximately 47% and 42%, which were significantly higher than those in the LB control group and the two control groups without Cm recombinant protein, which proves that the cytotoxicity of Cm recombinant protein can effectively induce apoptosis of iBCAFs cells. intimin fap and EcB1SA YeeJ Overnight incubation of the supernatant of the culture medium of the fap strain can also reduce cell activity to a certain extent, because certain cytokines naturally secreted by bacteria can also have toxic effects on cells.
[0176] Similarly, EcB1SA, which does not secrete Cm recombinant protein, intimin fap and EcB1SA YeeJ fap strain and EcB1SA secreting Cm recombinant protein intimin fapCm and EcB1SA YeeJ The fapCm strain was co-cultured with iBCAFs cells for 4 h to verify the ability of the engineered bacteria to target and induce cell apoptosis. Fig.23 and Fig.25 The results of flow cytometric analysis to detect the cell activity of iBCAFs and statistical analysis after three biological replicates are shown respectively.
[0177] like Fig.23 and Fig.25 As shown, compared with the Mock negative control group under normal culture conditions, EcB1SA intimin fap and EcB1SA YeeJ Co-culture of the fap strain with iBCAFs cells for 4 h can significantly reduce cell activity, indicating that after the engineered bacteria adhere to the periphery of the cells, it will greatly affect the survival state of the cells and induce nearly 50% of the iBCAFs cells to die. intimin fap and EcB1SA YeeJ Compared with the fap strain, EcB1SA intimin fapCm and EcB1SA YeeJ The fapCm strain increased the toxicity of the Cm recombinant protein on the basis of targeted adhesion, increased the early apoptosis rate of iBCAFs cells, and further reduced the activity of iBCAFs cells to about 35%. intimin fapCm and EcB1SA YeeJ The effect of inducing cell apoptosis by co-culturing fapCm engineered bacteria with iBCAFs cells for 4 hours was basically consistent with the cell apoptosis after overnight incubation with Cm recombinant protein.
[0178] The above results show that Cm recombinant protein can indeed effectively induce cell apoptosis. And the targeted adhesion of engineered bacteria around iBCAFs cells will have a significant impact on cell activity. On the basis of targeted adhesion of engineered bacteria, the simultaneous secretion of Cm recombinant protein can accelerate the induction of cell apoptosis.
[0179] Example 9. In vivo verification of the tumor treatment effect of the EcB1SAfapCm engineered bacteria
[0180] First, a mouse colon cancer model was constructed, and the experimental method was the same as in Example 7. When the tumor volume reached 150-300 mm 3 The tumor-bearing mice were randomly divided into 4 groups, and 1×10 8 CFEcB1 intimin , EcB1SA intimin fap, EcB1SA intimin fapCm and 100 μL PBS.
[0181] Fig.26 The distribution of bacteria was detected by in vivo imaging after 24 hours. It can be seen that all strains are only distributed in the tumor site.
[0182] Fig. 27 EcB1SA intimin and EcB1SA intimin 24 hours after the injection of fap engineered bacteria, the mouse tissues were dissected and imaged. The results were the same as those of the tail vein injection of engineered bacteria in Example 7. The engineered bacteria were injected at the tumor site, EcB1SA intimin fap is targeted and enriched in the tumor cortex, while EcB1SA intimin Since it is not interfered by the affinity of antigen and antibody, it can successfully enter the tumor and colonize. intimin fap has a strong ability to specifically target CAFs.
[0183] Fig.28 The statistical results of tumor volume changes in each group of tumor-bearing mice within 15 days. Compared with other groups, EcB1SA intimin The tumor volume of the tumor-bearing mice in the fapCm experimental group was always below 500mm 3 . Proof EcB1SA intimin The effective colonization of fapCm in mouse tumors and the cytotoxicity of Cm recombinant protein can effectively inhibit tumor growth rate and produce tumor regression effect.
[0184] Fig.29 The weight changes of tumor-bearing mice in each group within 15 days. intiminThe weight of mice in the fapCm experimental group was lower, but overall it was still increasing. intimin Intratumoral injection of fapCm had no effect on the growth of mice.
[0185] Fig.30 HE staining of tumor sections was performed to detect pathological changes inside the tumor. intimin Compared with the treatment group, EcB1SA intimin fap and EcB1SA intimin fapCm can significantly destroy tumor tissue, and EcB1SA intimin fapCm has stronger destructive power.
[0186] Fig.31 This is the result of IHC on tumor sections, which detects the distribution of FAP antigen and E. coli K / O antigen inside the tumor. intimin Compared with the treatment group, EcB1SA intimin fap and EcB1SA intimin A large number of engineered bacteria were enriched in the tumor sites of mice in the fapCm experimental group. Due to the targeted colonization and apoptosis induction of engineered bacteria, the distribution of FAP antigen was relatively diffuse. intimin fap and EcB1SA intimin fapCm can effectively colonize tumors, and EcB1SA intimin fapCm can effectively induce cell apoptosis, destroy tumor tissue, inhibit tumor growth and produce tumor regression effect by secreting Cm recombinant protein.
Claims
1. An engineered Escherichia coli, wherein one or more coding genes in the fimA to fimH operon of type I fimbriae are knocked out, and The cell membrane of the engineered Escherichia coli has a fusion protein, wherein the fusion protein comprises: A membrane anchoring domain, which includes the full length or a fragment thereof of an autotransporter protein derived from bacteria; and, targeting domain.
2. The engineered Escherichia coli according to claim 1, characterized in that The genome of the engineered Escherichia coli has a nucleotide sequence as shown in SEQ ID NO: 25 or 26, or a nucleotide sequence having at least 65% identity thereto.
3. The engineered Escherichia coli according to claim 1, characterized in that The engineered Escherichia coli is selected from BL21, MG1655, DH5α, Transetta, RosettaBlue, Origami, Rosetta or Trans5α.
4. The engineered Escherichia coli according to claim 1, characterized in that The membrane anchoring domain includes the full length or a fragment of a tight adhesion protein or a tight adhesion protein-like adhesion protein.
5. The engineered Escherichia coli according to claim 1, characterized in that The membrane anchoring domain comprises an amino acid sequence as shown in SEQ ID NO: 1 or 2, or an amino acid sequence having at least 85% sequence identity thereto.
6. The engineered Escherichia coli according to claim 1, characterized in that The targeting domain includes an antibody or an antigen-binding fragment thereof that specifically binds to tumor cells.
7. The engineered Escherichia coli according to claim 1, characterized in that The targeting domain comprises a single domain antibody against fibroblast activation protein.
8. The engineered Escherichia coli according to claim 1, characterized in that The E. coli also includes a cytotoxic molecule or an active fragment thereof.
9. The engineered Escherichia coli according to claim 8, characterized in that The cytotoxic molecules include IFNγ, GM-CSF, TNFα, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-16, IL-17, IL-23, IL-32, granzyme B, perforin or a combination thereof.
10. The engineered Escherichia coli according to any one of claims 1 to 9, characterized in that The fusion protein comprises the amino acid sequence shown in SEQ ID NO: 3 or 4, or an amino acid sequence having at least 85% sequence identity therewith.
11. A method for preparing the engineered Escherichia coli according to any one of claims 1 to 10.
12. The method according to claim 11, characterized in that The method comprises the following steps: 1) using the CRISPR / Cas gene editing system to knock out one or more coding genes in the fimA-fimH operon of type I fimbriae of Escherichia coli to obtain Escherichia coli with knocked-out fimbriae genes; and 2) expressing a fusion protein in the Escherichia coli in which the pilus gene is knocked out, wherein the fusion protein includes a membrane anchoring domain and a targeting domain.
13. The method according to claim 12, characterized in that In step 1), sgRNA targeting fimB and / or fimH is used. Wherein, the sgRNA targeting fimB has a nucleotide sequence as shown in SEQ ID NO: 15 and / or 16, or The sgRNA targeting fimH has a nucleotide sequence as shown in SEQ ID NO: 17 and / or 18.
14. The method according to claim 12, characterized in that The method further comprises expressing a cytotoxic molecule in the engineered E. coli.
15. A composition comprising the engineered Escherichia coli according to any one of claims 1 to 10, or a culture supernatant derived from the engineered Escherichia coli.
16. A method for detecting tumor cells, the method comprising using the engineered Escherichia coli according to any one of claims 1 to 10, and observing the aggregation of the engineered Escherichia coli around tumor cells.
17. Use of the engineered Escherichia coli according to any one of claims 1 to 10 in the preparation of an agent for detecting, preventing and / or treating tumors.
18. Use of the engineered Escherichia coli according to any one of claims 1 to 10 in screening antibodies or antigen-binding fragments thereof.
Citation Information
Patent Citations
Fibroblast binding agents and use thereof
CN112074267A
Engineering bacterium for targeted therapy of colorectal cancer as well as construction method and application of engineering bacterium
CN116987725A
Pharmaceutical composition for preventing or treating cancer comprising salmonella strain and immune checkpoint inhibitor as active ingredients
CN118338909A
Fibroblast binding agents and use thereof
US20210023167A1
Recombinant bacterium and uses thereof
US20240084312A1
